Neurocrine Biosciences
NBIX
$147.02
+8.86%
Neurocrine Biosciences Inc is a biopharmaceutical company focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders, with a portfolio that includes therapies for conditions like tardive dyskinesia, chorea associated with Huntington's disease, and classic congenital adrenal hyperplasia. The company has established itself as a commercial-stage leader in neuroscience and endocrine therapeutics, with a distinct identity built on its marketed flagship product Ingrezza and a growing pipeline of drug candidates. The current investor narrative is dominated by a strategic acquisition to bolster its rare disease pipeline and a recent stock price correction following conservative 2026 guidance for its key product, creating a debate between near-term execution concerns and long-term growth potential from its expanded portfolio.…
NBIX
Neurocrine Biosciences
$147.02
Related headlines
Investment Opinion: Should I buy NBIX Today?
Rating & Thesis: Hold. Neurocrine presents a compelling long-term growth story at a reasonable price, but near-term headwinds from guidance and technical deterioration warrant caution, aligning with a 'wait-and-see' approach despite bullish analyst consensus.
Supporting Evidence: The investment case is supported by four key data points: 1) The forward P/E of 9.97x is low for a company with 28.3% YoY revenue growth, 2) Robust free cash flow generation of $748.7M TTM provides strategic flexibility, 3) The PEG ratio of 0.71 suggests undervaluation relative to growth, and 4) The stock trades 82% of the way from its 52-week low, indicating it is in a potential value zone after a significant correction.
Risks & Conditions: The two biggest risks are the execution of Ingrezza's 2026 guidance and the successful integration of the Soleno acquisition. This Hold rating would upgrade to a Buy if the stock convincingly breaks above the $133.25 resistance level on strong Q1 2026 earnings, or if forward P/E compresses further toward 8x without a deterioration in growth estimates. It would downgrade to a Sell if quarterly revenue growth decelerates below 15% or if the stock breaks below the $124 support, signaling a test of the 52-week low. Relative to its own compressed valuation history and growth profile, the stock appears fairly valued to slightly undervalued, but not compelling enough to overcome near-term momentum risks.
Sign up to view all
NBIX 12-Month Price Forecast
The outlook is balanced with a slight tilt to the base case. The company's fundamentals are strong, but the market is rightly skeptical after the guidance shock. The low forward P/E offers protection, but the stock needs a catalyst to break out of its downtrend. The stance would upgrade to bullish on evidence that the Q4 growth rate of 28.3% is sustainable, or if the stock establishes a firm base above $133. It would turn bearish if quarterly revenues fall sequentially or if the $124 support level fails.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Neurocrine Biosciences's 12-month outlook, with a consensus price target around $191.13 and implied upside of +30.0% versus the current price.
Average Target
$191.13
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$118 - $191
Analyst target range
Analyst coverage for Neurocrine appears limited in the provided dataset, with only 5 analysts contributing to estimates, which suggests the stock may have a narrower institutional following typical of some commercial-stage biopharma names. The consensus sentiment, inferred from recent institutional ratings, is overwhelmingly bullish, with firms like JP Morgan, Wells Fargo, RBC Capital, Citigroup, Wedbush, Needham, and HC Wainwright all maintaining Buy or Outperform ratings as of February 2026, even after the stock's drop on guidance. The average revenue estimate for the period is approximately $5.15 billion, with a wide EPS estimate range from $12.91 to $16.12, indicating some variance in earnings projections. The target price range is not explicitly provided, but the wide dispersion in EPS estimates (a high of $16.12 versus a low of $12.91) signals meaningful uncertainty among analysts regarding the company's near-term profit trajectory. The high-end EPS estimate likely assumes successful integration of the Soleno acquisition, stronger-than-guided Ingrezza sales, and pipeline success, while the low-end may reflect concerns over competitive pressures, guidance execution risks, or acquisition-related integration costs. The recent reaffirmation of bullish ratings despite the stock drop suggests analysts view the sell-off as an overreaction, creating a potential buying opportunity for those with a longer-term horizon, though the limited number of contributing analysts warrants caution regarding the breadth of the consensus view.
Bulls vs Bears: NBIX Investment Factors
The evidence presents a sharp conflict between strong fundamentals and weak near-term sentiment. The bull case is anchored in robust revenue growth (28.3% YoY), exceptional profitability (97.8% gross margin), a fortress balance sheet, and a compelling forward P/E of 9.97x. The bear case is driven by a severe technical breakdown following disappointing 2026 guidance, recent significant underperformance versus the market, and high short interest signaling skepticism. Currently, the bearish near-term price action and guidance reset hold stronger immediate evidence, as the market is prioritizing execution risk over long-term value. The single most important tension is whether the conservative 2026 guidance for Ingrezza represents a temporary hiccup or the beginning of a sustained growth deceleration for the company's core asset.
Bullish
- Strong Revenue Growth & High Margins: Q4 2025 revenue grew 28.3% YoY to $805.5M, continuing a sequential quarterly ramp. The company boasts an exceptional gross margin of 97.82%, demonstrating the highly profitable nature of its specialty pharmaceutical portfolio.
- Attractive Forward Valuation: The forward P/E of 9.97x is compelling, representing a significant discount to the trailing P/E of 29.49x and implying strong expected earnings growth. The PEG ratio of 0.71 suggests the stock is undervalued relative to its earnings growth rate.
- Robust Balance Sheet & Cash Flow: The company has a strong financial position with a debt-to-equity ratio of 0.13 and a current ratio of 3.39. It generated $748.7M in TTM free cash flow, providing ample resources to fund the Soleno acquisition and pipeline development without financial strain.
- Analyst Bullishness Post-Selloff: Major firms (JP Morgan, Wells Fargo, etc.) maintained Buy ratings despite the stock's 10.6% drop on conservative 2026 guidance, viewing the sell-off as an overreaction. This creates a potential buying opportunity if their long-term growth thesis proves correct.
Bearish
- Key Product Guidance Disappointment: The stock plummeted from ~$137 to ~$123 in February 2026 on disappointing guidance for its flagship product, Ingrezza. This signals potential near-term growth deceleration and raises execution concerns, overshadowing strong historical performance.
- Recent Severe Technical Downtrend: The stock is down 7.98% over six months and trades near the lower end of its 52-week range ($107.96-$160.18). It has significantly underperformed the S&P 500 by -10.57% over the past month, indicating strong selling pressure and a lack of near-term catalysts.
- Earnings Volatility & Margin Pressure: Net income margin has fluctuated from 1.38% in Q1 2025 to 26.36% in Q3 2025, settling at 19.08% in Q4. This quarterly variability in profitability, despite high gross margins, suggests potential volatility in operating leverage and R&D spending.
- Limited Analyst Coverage & High Short Interest: Only 5 analysts contribute to estimates, indicating a narrower institutional following which can exacerbate volatility. A short ratio of 5.23 reflects significant bearish sentiment and skepticism in the market regarding the company's near-term prospects.
NBIX Technical Analysis
The stock is in a clear downtrend over the last six months, with the price declining -7.98% from its levels six months ago, and is currently trading at the lower end of its 52-week range, approximately 82% of the way from its 52-week low of $107.96 toward its high of $160.18. This positioning near the lower bound suggests the stock is approaching a potential value zone, but also indicates significant selling pressure and a lack of near-term momentum, as evidenced by a -0.59% one-month change. The short-term momentum is negative and diverges from the positive longer-term 1-year change of +23.63%, signaling a potential trend reversal or consolidation phase following the earlier strength, with the stock's beta of 0.35 indicating it has been significantly less volatile than the broader market during this recent decline. Recent momentum is decisively negative, with the stock down -0.59% over the past month and -3.15% over the past three months, a stark contrast to the S&P 500's gains of +9.98% and +4.14% over the same periods, respectively. This significant underperformance, highlighted by a -10.57 relative strength figure over one month, suggests the stock is experiencing a sharp, company-specific sell-off rather than a broad market-driven move. The price action shows a sharp drop in mid-February 2026 from the $137 range to near $123, and the stock has struggled to recover, remaining range-bound between approximately $127 and $133 for the past two months, indicating a lack of buying conviction. Key technical support is clearly defined at the 52-week low of $107.96, while resistance sits at the 52-week high of $160.18. A sustained break below the $124-$127 area, where the stock found a floor in February, could signal a test of the 52-week low, whereas a move above the recent consolidation high near $133.25 is needed to suggest a reversal. The stock's low beta of 0.35 indicates it is historically 65% less volatile than the market, which may limit the magnitude of further downside moves but also suggests muted upside potential in strong market rallies, a factor crucial for risk-adjusted portfolio positioning.
Beta
0.34
0.34x market volatility
Max Drawdown
-20.9%
Largest decline past year
52-Week Range
$116-$160
Price range past year
Annual Return
+23.6%
Cumulative gain past year
| Period | NBIX Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | +11.4% |
| 3m | +6.6% | +8.3% |
| 6m | -3.5% | +9.4% |
| 1y | +23.6% | +31.3% |
| ytd | +4.6% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NBIX Fundamental Analysis
Neurocrine's revenue trajectory remains robust, with Q4 2025 revenue of $805.5 million representing a 28.3% year-over-year increase, continuing a multi-quarter trend of strong growth from $572.6 million in Q1 2025. The sequential quarterly revenue pattern shows consistent expansion: $572.6M (Q1), $687.5M (Q2), $794.9M (Q3), and $805.5M (Q4), indicating accelerating top-line performance driven primarily by its product sales, which constituted $798.3 million of the total Q4 revenue. This growth trajectory underscores the commercial execution of its core therapies, though recent guidance suggests a potential deceleration may be anticipated. The company is solidly profitable, with Q4 2025 net income of $153.7 million and an exceptionally high gross margin of 97.82%. Profitability has shown some quarterly variability, with net income margins of 1.38% in Q1, 15.64% in Q2, 26.36% in Q3, and 19.08% in Q4, reflecting potential fluctuations in operating leverage and R&D investment. The operating margin for Q4 was 21.64%, demonstrating the company's ability to convert its high gross margin into substantial operating earnings, a hallmark of its commercial-stage success in specialty pharmaceuticals. Neurocrine maintains a strong balance sheet with a healthy current ratio of 3.39 and a low debt-to-equity ratio of 0.13, indicating ample liquidity and minimal financial leverage. The company generated robust free cash flow of $748.7 million on a TTM basis, providing significant internal funding for its growth initiatives and the recent Soleno Therapeutics acquisition. With a return on equity (ROE) of 14.71%, the company is efficiently generating shareholder returns from its equity base, supported by its profitable operations and clean capital structure.
Quarterly Revenue
$805500000.0B
2025-12
Revenue YoY Growth
+0.28%
YoY Comparison
Gross Margin
+0.97%
Latest Quarter
Free Cash Flow
$748700000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NBIX Overvalued?
Given the company's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 29.49x, while the forward P/E is significantly lower at 9.97x, indicating the market expects a substantial increase in earnings. The large gap between trailing and forward multiples suggests analysts are forecasting significant EPS growth, aligning with the estimated EPS average of $14.15 for the coming period, a dramatic increase from the trailing diluted EPS of $1.48. Compared to sector averages, Neurocrine's trailing P/E of 29.49x and Price/Sales of 4.93x are not directly comparable without industry benchmark data, but the forward P/E of 9.97x appears attractive if growth expectations are met. The stock's PEG ratio of 0.71, based on trailing metrics, suggests it may be undervalued relative to its earnings growth rate, a point often highlighted in value-oriented analyses. The EV/EBITDA of 20.72x provides another lens, reflecting the market's valuation of the company's operating profitability. Historically, the stock's own valuation has compressed; the current trailing P/E of 29.49x is below the 52-week high P/E levels seen in prior quarters (e.g., 348.95 in Q1 2025 and 54.32 in Q2 2024) as earnings have normalized. The current P/S ratio of 4.93x is also near the lower end of its recent historical range, which has seen figures above 20x during periods of lower revenue. This historical context suggests the stock is trading at a more reasonable valuation relative to its own history, potentially pricing in the recent guidance reset and offering a more stable entry point for long-term investors.
PE
29.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -277x~349x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Neurocrine's primary financial risk is earnings volatility, as evidenced by net income margins swinging from 1.38% to 26.36% over the past year. While the balance sheet is strong (D/E 0.13), the company faces revenue concentration risk with its flagship product, Ingrezza, driving the majority of its $805.5M quarterly sales. The recent conservative 2026 guidance for this product introduces uncertainty around the sustainability of its 28.3% YoY growth rate. Furthermore, the Soleno acquisition, while strategic, carries integration and pipeline development execution risks that could pressure margins.
Market & Competitive Risks: The stock trades at a forward P/E of 9.97x, which appears attractive but follows a period of severe multiple compression from historical extremes. The key market risk is that this valuation fails to expand if growth concerns persist, leaving the stock range-bound. Competitive risks in the neuroscience and rare disease spaces are ever-present and could pressure Ingrezza's market share or the commercial potential of new pipeline assets. The stock's low beta of 0.35 suggests it has been less volatile than the market, but its recent -10.57% relative underperformance over one month highlights intense company-specific selling pressure unrelated to broader indices.
Worst-Case Scenario: The worst-case scenario involves a confirmation of the guidance fears, where Ingrezza sales growth stalls or declines due to competition or market saturation, coupled with setbacks in the Soleno integration or pipeline. This could trigger analyst downgrades, a flight of remaining investor confidence, and a test of major technical support. The realistic downside would be a retest of the 52-week low of $107.96, which represents a potential loss of approximately -18% from the current price of ~$131.78. Given the stock's recent max drawdown of -23.21%, a move toward this level is within recent historical volatility.
FAQ
The key risks are, in order of severity: 1) Execution Risk: Failure to meet or exceed the newly conservative 2026 guidance for its key product, Ingrezza. 2) Sentiment & Technical Risk: The stock is in a pronounced downtrend with high short interest (5.23), which can fuel further declines. 3) Pipeline & Acquisition Risk: Challenges in integrating Soleno Therapeutics or setbacks in clinical pipeline development. 4) Competitive Risk: Erosion of market share for Ingrezza from existing or new competitors in the neurological treatment space.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $130 and $150 as it meets tempered guidance. The Bull Case (30% probability) targets $155 to $170 on stronger-than-expected execution and restored confidence. The Bear Case (20% probability) warns of a drop to $108-$125 if growth concerns intensify. The Base Case is most likely, hinging on the assumption that the company delivers on its reset 2026 expectations without further negative surprises.
Based on forward earnings, NBIX appears undervalued. Its forward P/E of 9.97x is low for a company with its growth profile and profitability, and the PEG ratio of 0.71 traditionally signals undervaluation. However, this must be weighed against its own valuation history; the trailing P/E has compressed from over 300x to 29.49x as earnings normalized. Relative to its current growth trajectory, the stock is fairly valued to slightly undervalued, but the market is clearly applying a discount due to near-term execution concerns.
NBIX is a complex buy at current levels. It offers a compelling valuation with a forward P/E of 9.97x and strong fundamentals like 97.8% gross margins and a clean balance sheet. However, it comes with significant near-term risk, as evidenced by its -7.98% six-month decline and high short interest of 5.23. It could be a good buy for long-term, risk-tolerant investors who believe the guidance reset was overly punitive, but short-term traders should be wary of the ongoing downtrend and lack of positive momentum.
NBIX is more suitable for a long-term investment horizon of 2-3 years minimum. Its low beta of 0.35 indicates it is not a high-momentum trading stock, and the current investment thesis revolves around the long-term integration of an acquisition and pipeline development. Short-term volatility is high due to sentiment swings, but the company's strong cash flow and market position support a long-term growth story. Investors should be prepared to hold through potential near-term volatility related to quarterly earnings and guidance.